Nearly 100,000 bottles of a type of drug used to treat chronic kidney disease and other conditions are being recalled due to possible carcinogens, according to a notice published by the Food and Drug Administration this week.
In three separate notices published this week on the FDA’s website, a combined 91,824 bottles of cinacalcet hydrochloride tablets in different strengths are being recalled due to the presence of a nitrosamine, N-nitroso-cinacalcet, found to be above the FDA’s acceptable daily intake levels.
The company that manufactured the cinacalcet hydrochloride tablets is Cipla USA, based in Warren, New Jersey. Cipla USA is owned by the global pharmaceutical company, Cipla Ltd., which is based in Mumbai, India….